Details for Patent: 10,420,734

Which drugs does patent 10,420,734 protect, and when does it expire?

Patent 10,420,734 protects ORSERDU and is included in one NDA.

This patent has thirty-four patent family members in nineteen countries.

Summary for Patent: 10,420,734

Title:	Method of treating cancer using selective estrogen receptor modulators
Abstract:	Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Inventor(s):	Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
Assignee:	Duke University
Application Number:	US15/129,197
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,420,734

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No	10,420,734					TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes	10,420,734					TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY

International Family Members for US Patent 10,420,734

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3122426		CA 2024 00007	Denmark
European Patent Office	3122426		2024C/505	Belgium
European Patent Office	3122426		301263	Netherlands
European Patent Office	3122426		LUC00331	Luxembourg
European Patent Office	3122426		PA2024504	Lithuania
European Patent Office	3122426		122024000013	Germany